olivLaw · US equity research
Caring Brands, Inc. CABR
Perfumes, Cosmetics & Other Toilet Preparations · SIC 2844 · Vertical: Perfumes, Cosmetics & Other Toilet Preparations (SIC 2844)
Caring Brands is a wellness consumer products company developing OTC and cosmetic products for conditions such as hair loss, eczema, psoriasis and vitiligo, still in an early commercial stage. In fiscal 2025 it reported nominal revenue of $4,215 and a net loss of $6,278,191, so interest in the company remains tied to whether its portfolio can turn into real sales.
At the close of 04 Nov 2026, Caring Brands, Inc. (CABR) stock was 0.90 USD (−26.83% on the day), with market capitalisation 9.3 m USD, beta 0.62, 52-week range 0.75–1.61 USD. Latest reported quarter (Q2 2026): net income of -638.7 k USD, diluted EPS -0.10 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 37.8
- weak (30–45)
- Bollinger (20, 2)
- 0.93 – 1.36
- below the lower band · %B -0.07 · band width 37.6%
- SMA 50 / 200
- 1.21 / 1.14
- mixed trend
- MACD (12, 26, 9)
- -0.05 / -0.04
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −20.4% | −1.1% | −19.3 pp | — |
| 3 months | −42.3% | −0.5% | −41.9 pp | — |
| 6 months | −4.5% | +4.4% | −8.9 pp | — |
| Year to date | +4.9% | +12.3% | −7.4 pp | — |
| 1 year | unavailable | +13.5% | unavailable | +9.7% |
| 3 years | unavailable | +76.4% | unavailable | −13.5% |
| 5 years | unavailable | +63.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | 465 | 1.5 k | 1.6 k | 740 | 420 | — | — |
| Cost of revenue | — | 2.1 k | 678 | 722 | 292 | 181 | — | — |
| Gross profit | — | -1.6 k | 791 | 865 | 448 | 239 | — | — |
| Research & development | — | 0 | — | — | — | 0 | — | — |
| SG&A | 156.1 k | 26.5 k | 30.2 k | 21.3 k | 999.9 k | -2.1 m | 88.5 k | 26.2 k |
| Operating income | -156.1 k | -872.8 k | -539.3 k | -659.6 k | -999.5 k | -3.7 m | -1.7 m | -638.7 k |
| Depreciation & amortisation | — | 150.0 k | 75.0 k | 75.0 k | — | — | — | — |
| Interest expense | 67 | -10.0 k | 427 | 0 ≈ | 19.3 k | -554 | 287.0 k | 39 |
| Income tax | — | — | 0 | 0 ≈ | — | — | 0 | 0 ≈ |
| Net income | -156.2 k | -862.8 k | -538.8 k | -660.6 k | -1.0 m | -4.1 m | -2.0 m | -638.7 k |
| Diluted EPS | — | -0.07 | -0.04 | -0.05 | -0.08 | -0.28 ≈ | -0.27 | -0.10 |
| Operating cash flow | — | -272.2 k | -241.8 k | -209.3 k ≈ | -180.8 k ≈ | -1.1 m | -550.8 k | -463.1 k ≈ |
| Share repurchases | — | — | — | — | — | — | 3.1 m | 0 ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | unavailable | 4.2 k |
| Revenue YoY | unavailable | unavailable |
| Net income | -1.5 m | -6.3 m |
| Net income YoY | unavailable | unavailable |
| Diluted EPS | unavailable | -0.46 |
| Diluted EPS YoY | unavailable | unavailable |
| net % | unavailable | -148,948.8% |
| Free cash flow | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 2.2 m USD
- Financial debt
- 58.7 k USD
- Net debt
- -2.1 m USD
- Equity
- 2.1 m USD
- Total assets
- 2.3 m USD
- Debt / equity
- 0.03x
- Current ratio
- 13.16x
- ROE
- -217.1%
- ROA
- -202.4%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Income statement · USD
| Line | 2024 | 2025 | Source (latest year) |
|---|---|---|---|
| Revenue | — | 4.2 k | SEC (XBRL)· 31 Mar 2026verified |
| Cost of revenue | — | 1.9 k | SEC (XBRL)· 31 Mar 2026verified |
| Gross profit | — | 2.3 k | SEC (XBRL)· 31 Mar 2026verified |
| Research & development | 39.6 k | 0 | SEC (XBRL)· 31 Mar 2026verified |
| SG&A | — | 147.7 k | SEC (XBRL)· 31 Mar 2026verified |
| Operating income | — | -5.9 m | SEC (XBRL)· 31 Mar 2026verified |
| Depreciation & amortisation | — | 300.0 k | SEC (XBRL)· 31 Mar 2026verified |
| EBITDA | — | -5.6 m ≈ | SEC (XBRL)· 31 Mar 2026derived |
| Interest expense | — | 19.2 k | SEC (XBRL)· 31 Mar 2026verified |
| Income tax | 0 | 0 | SEC (XBRL)· 31 Mar 2026verified |
| Net income | -1.5 m | -6.3 m | SEC (XBRL)· 31 Mar 2026verified |
| Diluted EPS | — | -0.46 | SEC (XBRL)· 31 Mar 2026verified |
| Weighted average diluted shares | — | 13.6 m | SEC (XBRL)· 31 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2024 | 2025 | Source (latest year) |
|---|---|---|---|
| Cash | 469.0 k | 2.2 m | SEC (XBRL)· 31 Mar 2026verified |
| Inventories | 13.7 k | 12.8 k | SEC (XBRL)· 31 Mar 2026verified |
| Current assets | 527.5 k | 2.3 m | SEC (XBRL)· 31 Mar 2026verified |
| Intangibles (excl. goodwill) | 2.9 m | 2.6 m | SEC (XBRL)· 31 Mar 2026verified |
| Total assets | 3.9 m | 2.3 m | SEC (XBRL)· 31 Mar 2026verified |
| Accounts payable | 169.4 k | 170.4 k | SEC (XBRL)· 31 Mar 2026verified |
| Long-term debt | — | 58.7 k | SEC (XBRL)· 31 Mar 2026verified |
| Current liabilities | 186.1 k | 176.8 k | SEC (XBRL)· 31 Mar 2026verified |
| Total liabilities | 186.1 k | 235.5 k | SEC (XBRL)· 31 Mar 2026verified |
| Equity | 3.7 m † | 2.1 m † | SEC (XBRL)· 31 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2024 | 2025 | Source (latest year) |
|---|---|---|---|
| Operating cash flow | — | -1.7 m | SEC (XBRL)· 31 Mar 2026verified |
| Financing cash flow | — | 3.4 m | SEC (XBRL)· 31 Mar 2026verified |
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 3 of at least 6
- score weight coverage: 16.7% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 9.3 m USD
Key indicators
Coverage and freshness
Score by group
17% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 3 of at least 6; score weight coverage: 16.7% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -183,298.7% | 0 (vs peers) | 38% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -23.2x | 0 (on a fixed band) | 38% |
| Current ratio · Balance sheet | 5.0x | 100 (on a fixed band) | 25% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partial0/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Caring Brands, Inc. (CABR). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 4.2 k USD in 2025; net margin -183,298.7%; ROE -3,889.1%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 3 of at least 6; score weight coverage: 16.7% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 5.0x
What contradicts it
- Net margin: -183,298.7%
- Interest coverage: -23.2x
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Perfumes, Cosmetics & Other Toilet Preparations (SIC 2844) · same industry (4-digit SIC) · compared with 15 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| CLColgate-Palmolive Company | 78.5 bn | 38.7 | 358.9% | 9.6% | +1.4% | +23% / +25% |
| KVUEKenvue Inc. | 37.1 bn | 21.9 | 16.3% | 10.9% | −2.1% | +34% / +4% |
| ELFe.l.f. Beauty, Inc. | 6.7 bn | 113.6 | 6.0% | 3.4% | +24.6% | +49% / −4% |
| IPARInterparfums, Inc. | 4.0 bn | 23.3 | 19.5% | 11.3% | +2.5% | +52% / −1% |
| COTYCoty Inc. | 3.1 bn | — | -18.5% | -10.4% | −1.5% | +5% / −70% |
| EPCEdgewell Personal Care Company | 1.4 bn | — | -6.2% | -4.2% | −1.3% | +66% / −15% |
| SLSNSolesence, Inc. | 64.6 m | — | -15.1% | -3.8% | +18.6% | −60% / +22% |
| AXILAxil Brands, Inc. | 38.2 m | 16.7 | 23.3% | 9.3% | +17.5% | +10% / unavailable |
| UGUnited-Guardian, Inc. | 31.5 m | 12.8 | 21.4% | 22.0% | −13.4% | +18% / −16% |
| CABRCaring Brands, Inc. | 9.3 m | — | -3,889.1% | -183,298.7% | unavailable | unavailable / unavailable |
| BNKKBonk, Inc. | 9.3 m | — | -332.4% | -2,330.4% | +201.6% | −82% / −99% |
| YCBDcbdMD, Inc. | 4.5 m | — | -40.3% | -13.8% | −1.5% | −34% / −93% |
| ELEstee Lauder Companies Inc | — | 111.7 | 9.3% | 2.4% | +5.0% | +19% / −12% |
| ODDOddity Tech Ltd | — | 12.0 | 32.6% | 13.7% | +25.2% | −50% / −37% |
| HLNHaleon plc | — | — | 10.2% | 15.1% | −1.8% | −6% / +8% |
| YSGYatsen Holding Limited | — | — | -2.7% | -1.9% | +32.2% | −67% / −49% |
1- and 3-year price returns: for CABR from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Caring Brands is a wellness consumer products company developing OTC and cosmetic products for conditions such as hair loss, eczema, psoriasis and vitiligo, still in an early commercial stage. In fiscal 2025 it reported nominal revenue of $4,215 and a net loss of $6,278,191, so interest in the company remains tied to whether its portfolio can turn into real sales.
SWOT
Strengths
- The portfolio spans several dermatological and wellness conditions, and some products have published clinical studies.
- The company raised funds through its initial public offering and private placement, giving it a cash base for development.
- Licensing agreements with partners in India and Japan allow expansion without large investment in in-house production.
Weaknesses
- Sales are nearly nonexistent, and the company does not yet have a dedicated sales and marketing team.
- Net losses are significant, and working capital is strained by payroll and professional service costs.
- The operating history is short, and the withdrawal of Photocil from the US market points to difficulty turning products into sales.
Opportunities
- A US relaunch and expanded licensing in more countries could generate new revenue.
- If the eczema product reformulation is completed, an online launch could open a category with strong demand.
- Sales through online platforms could extend reach without an extensive physical distribution network.
Threats
- Competition in the skin care and hair growth segments is intense, and barriers to entry are low.
- Meeting FDA requirements and local regulations could delay launches or raise costs.
- If additional financing is not available on acceptable terms, operations could be reduced or halted.
Risks
- Going-concern uncertaintyhigh
The annual report cites a working capital deficiency and limited operations, which raise serious doubt about the company's ability to continue without new financing.
- Lack of significant saleshigh
Revenue is negligible, and without a sales and marketing network, product relaunches could fail to produce commercial impact, as happened with the Photocil withdrawal from the US.
- Impairment of intangible assetsmedium
The company has recorded impairments on its intellectual property license and an investment. If sales are delayed, further asset impairments could arise.
- Dependence on licensees and manufacturersmedium
The company does not directly control every stage of production or compliance with health and safety standards, which could lead to interruptions, recalls or product liability.
- Dilution from additional financingmedium
The private placement included convertible redeemable preferred stock and warrants, and share repurchases changed the capital structure. Future financing could reduce existing shareholders' stake.
Investment thesis
What would need to be true (bull case)
- If US and non-India launches succeed, the portfolio of dermatological and wellness products could generate revenue that supports the company's development.
- The eczema product's dual-action mechanism and published clinical studies could offer a differentiation advantage if the reformulation is completed successfully.
- Licensing deals with partners in Japan and the Asia-Pacific region could bring milestone payments and royalties without high production costs.
What would break the thesis
- The company has no significant revenue and high net losses, which could force new financing on unfavorable terms.
- The report warns of going-concern risk, and if financing does not materialize, operations could be reduced or stopped.
- The withdrawal of Photocil from the US due to insufficient sales shows that turning products into revenue is uncertain and could repeat.
What to watch
- First-quarter results and the pace of personnel and professional service spendingQ3 2026
- Timing of the Photocil US relaunch and receipt of the NDC code2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Caring Brands, Inc., a Nevada corporation, presents itself as a wellness consumer products company with a portfolio of OTC and cosmetic products covering hair loss, eczema and psoriasis, vitiligo and a jellyfish-sting protective suncare line. According to the fiscal 2025 annual report, the company states that each product has an established mechanism of action, efficacy determined through controlled clinical trials, patent protection and acceptable commercial stability.
The company has not yet generated significant revenue. Fiscal 2025 revenue was $4,215, and the net loss of $6,278,191 included a $2,550,000 impairment of its intellectual property license, reflecting a business still in development and launch. The first half of 2026 shows no revenue, with a larger net loss attributable to common stockholders driven by preferred stock accretion and share repurchases.
Segments
Sun protection
NoStingz is a sunscreen product intended to protect against both UV rays and jellyfish stings. The company has not yet set a commercial launch timeline for this line.
Market context
Management presents phototherapy as a market with growth potential, but states that actual growth depends on market conditions, regulation and competition. For India, where the company and its licensee sell products, market data is limited and building a sales network remains essential to market penetration.
Trends
- Rising prevalence of skin conditionstailwind
Estimates cited by the company point to a high prevalence of psoriasis and vitiligo in India, which could support demand for affordable OTC treatments. The effect, however, depends on the company's ability to reach patients.
- Tightening regulatory frameworkheadwind
Products are marketed as cosmetics or OTC products compliant with local rules, and a US relaunch requires FDA registration and an NDC code. Compliance requirements could delay launches and raise costs.
- Consumer interest in OTC and wellness productsmixed
Consumer demand for over-the-counter wellness products may support sales on online platforms such as Amazon, where the company already distributes. Intense competition in the segment limits that advantage.
- Reliance on licensing and manufacturing partnersmixed
Sales depend on external licensees and manufacturers in India and Florida. This could speed geographic expansion, but may also limit the company's control over quality and commercial timing.
Competitive position
The company describes the skin care and hair growth markets as intensely competitive, with established brands and far greater financial resources than its own. Low barriers to entry let new competitors quickly launch similar products.
The report does not name directly listed competitors, but refers to large health, medical therapy, cosmetics and consumer product manufacturers, as well as well-known brands in the eczema and psoriasis treatment segments. The company's differentiation rests on its dual-action mechanism and published clinical studies.
- Large pharmaceutical and dermatology treatment makers
Companies with greater financial and managerial resources, active in psoriasis and eczema treatments.
- Cosmetics and skin care manufacturers
Established brands competing for consumer attention in the skin care category.
- Hair loss treatment brands
Competitors in the hair growth segment, where minoxidil is the main OTC treatment.
- Consumer product and distribution companies
Large suppliers distributing a broad range of consumer goods to retailers with greater brand recognition.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report22 Oct 2026Item 3.03 · Amendments to articles or bylaws · Financial statements and exhibits
- Current report22 Sept 2026Material agreement · Departure or appointment of officers · Financial statements and exhibits
- Current report11 Sept 2026Item 3.02 · Regulation FD disclosure · Financial statements and exhibits
- Current report10 Sept 2026Material agreement · Departure or appointment of officers · Financial statements and exhibits
- Current report02 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Current report01 Sept 2026Item 3.02 · Other events
- Current report25 Aug 2026Material agreement · Item 3.02 · Amendments to articles or bylaws · Financial statements and exhibits
- Quarterly report13 Aug 2026
- Current report06 Aug 2026Other events · Financial statements and exhibits
- Current report17 Jul 2026Delisting notice
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Caring Brands, Inc. · 31 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Caring Brands, Inc. · 13 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.